These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22773165)

  • 41. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.
    Risinger R; Bhagwagar Z; Luo F; Cahir M; Miler L; Mendonza AE; Meyer JH; Zheng M; Hayes W
    Psychopharmacology (Berl); 2014 Jun; 231(11):2299-310. PubMed ID: 24337079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validity and reliability of extrastriatal [
    Svensson JE; Schain M; Plavén-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
    Neuroimage; 2019 Nov; 202():116143. PubMed ID: 31473354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.
    Ginovart N; Galineau L; Willeit M; Mizrahi R; Bloomfield PM; Seeman P; Houle S; Kapur S; Wilson AA
    J Neurochem; 2006 May; 97(4):1089-103. PubMed ID: 16606355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The D2 receptor occupancy profile of loxapine determined using PET.
    Kapur S; Zipursky RB; Jones C; Remington GJ; Wilson AA; DaSilva J; Houle S
    Neuropsychopharmacology; 1996 Dec; 15(6):562-6. PubMed ID: 8946430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [(11)C]raclopride-a positron emission tomography study in Macaca mulatta.
    Kortekaas R; Maguire RP; Cremers TI; Dijkstra D; van Waarde A; Leenders KL
    J Cereb Blood Flow Metab; 2004 May; 24(5):531-5. PubMed ID: 15129185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [
    Shin S; Kim S; Seo S; Lee JS; Howes OD; Kim E; Kwon JS
    Transl Psychiatry; 2018 Apr; 8(1):87. PubMed ID: 29686254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
    Catafau AM; Bullich S; Nucci G; Burgess C; Gray F; Merlo-Pich E;
    J Nucl Med; 2011 Apr; 52(4):526-34. PubMed ID: 21421726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
    Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
    Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
    Davis RE; Vanover KE; Zhou Y; Brašić JR; Guevara M; Bisuna B; Ye W; Raymont V; Willis W; Kumar A; Gapasin L; Goldwater DR; Mates S; Wong DF
    Psychopharmacology (Berl); 2015 Aug; 232(15):2863-72. PubMed ID: 25843749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of dopamine D
    Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
    Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
    Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.
    Wadenberg ML; Kapur S; Soliman A; Jones C; Vaccarino F
    Psychopharmacology (Berl); 2000 Jul; 150(4):422-9. PubMed ID: 10958084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.
    Appel L; Geffen Y; Heurling K; Eriksson C; Antoni G; Kapur S
    Eur Neuropsychopharmacol; 2009 Dec; 19(12):841-50. PubMed ID: 19717284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers.
    Brooks DJ; Papapetropoulos S; Vandenhende F; Tomic D; He P; Coppell A; O'Neill G
    Clin Neuropharmacol; 2010; 33(2):55-60. PubMed ID: 20375654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.